☆ 4.6 Letter

Incident users of tyrosine kinase inhibitors in patients with chronic myeloid leukemia: Analysis of anticancer treatment trajectories-A French population-based study using the French national health data system

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Related references

Note: Only part of the references are listed.
Article Hematology

Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study

Dragana Milojkovic et al.

Summary: The management of chronic myeloid leukaemia (CML) has evolved significantly, but real-world data shows discrepancies with ELN recommendations. Molecular assessments are often missed, some patients do not switch TKI despite treatment failure, and cardiovascular risk factors are not consistently considered during TKI management. Different TKIs have varying effects on achieving major and deep molecular responses, highlighting the need for improvement in caring for CML patients.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection
Article Oncology

Patterns of Tyrosine Kinase Inhibitor Utilization in Newly Treated Patients With Chronic Myeloid Leukemia: An Exhaustive Population-Based Study in France

Marie Pajiep et al.

Summary: Analysis of incident cases of chronic myeloid leukemia (CML) in France from 2011 to 2014 revealed a higher incidence rate in men and a peak at ages 75-79. Most patients initiated treatment with imatinib as their first-line TKI, with a significant portion switching to other TKIs within the first year. During follow-up, a considerable number of patients discontinued or suspended TKI therapy. Additionally, patients presented with comorbidities and polypharmacy, highlighting the potential risk of drug-drug interactions during TKI treatment.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection
Article Oncology

Using healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: A nationwide population-based study

Stephanie Foulon et al.

CANCER MEDICINE (2019)

Add to Collection
Article Hematology

Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Ruediger Hehlmann et al.

AMERICAN JOURNAL OF HEMATOLOGY (2019)

Add to Collection
Review Hematology

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

Michele Baccarani et al.

BLOOD (2013)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.